Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.
Also called NCT07493304
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,600 participants
- Sponsor
- Registry
-
NCT07493304 -
2024-519299-16-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Bulgaria, Japan, Romania, South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07493304. Randomized; no masking; primary purpose treatment. Start 2026-08-26 (actual); primary completion 2031-07-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- Acronym
- ROXI-CAT-II
- Condition
- Venous Thromboembolism (VTE)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07493304- Content hash
515a4bab0362708a3fb8e94235ef397e79666787463250e2d68cb6deee705f5c